

## WLSEAGPVVTVRALRGTGSW

**Cat. No.:** HY-P3436  
**CAS No.:** 771479-86-8  
**Molecular Formula:** C<sub>97</sub>H<sub>152</sub>N<sub>28</sub>O<sub>27</sub>  
**Molecular Weight:** 2142.42  
**Sequence Shortening:** WLSEAGPVVTVRALRGTGSW  
**Target:** Apoptosis  
**Pathway:** Apoptosis  
**Storage:** Sealed storage, away from moisture  
 Powder    -80°C    2 years  
              -20°C    1 year

WLSEAGPVVTVRALRGTGSW

\* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (46.68 mM); ultrasonic and warming and heat to 60°C)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	0.4668 mL	2.3338 mL	4.6676 mL
	5 mM	0.0934 mL	0.4668 mL	0.9335 mL
	10 mM	0.0467 mL	0.2334 mL	0.4668 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

WLSEAGPVVTVRALRGTGSW is a cardiomyocyte specific peptide. WLSEAGPVVTVRALRGTGSW-expressing exosomes can improve specific uptake by cardiomyocytes, decrease cardiomyocyte apoptosis, and enhance cardiac retention following intramyocardial injection in vivo<sup>[1][2]</sup>.

### REFERENCES

[1]. McGuire MJ, et, al. In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo. J Mol Biol. 2004 Sep 3;342(1):171-82.

[2]. Mentkowski KI, et, al. Exosomes Engineered to Express a Cardiomyocyte Binding Peptide Demonstrate Improved Cardiac Retention in Vivo. Sci Rep. 2019 Jul 11;9(1):10041.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA